Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

Who Took Part

According to the abstract, 120 women were involved.

PubMed tags the participants as women only.

Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

Everyone knew when Teriparatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The primary endpoint in the final analysis was the incidence of morphometric vertebral fracture during the 120-week follow-up period.

What Was Measured

PubMed files the paper under topics including Alendronate, Osteoporotic Fractures, Teriparatide, Bone Density Conservation Agents, Spinal Fractures, East Asian People and Osteoporosis.

Author keywords: Anabolic agent, Sequential therapy and Vertebral fracture.

What This Means in Plain Language

The paper is a randomized and open-label study of Teriparatide in 120 women.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.